Advanced

The impact of age on survival of diffuse large B-cell lymphoma - a population-based study

Hedstrom, Gustaf; Hagberg, Oskar LU ; Jerkeman, Mats LU and Enblad, Gunilla (2015) In Acta Oncologica 54(6). p.916-923
Abstract
Background. For Diffuse large B-cell lymphoma (DLBCL), the International Prognostic Index is the major tool for prognostication and considers an age above 60 years as a risk factor. However, there are several indications that increasing age is associated with more biological complexity, resulting in differences in DLBCL biology depending on age. Methods. We conducted a registry-based retrospective cohort study of all Swedish DLBCL patients diagnosed 2000-2013, to evaluate the importance of age at diagnosis for survival of DLBCL patients. Results. In total, 7166 patients were included for further analysis. Survival declined for every 10-year age group and every age group above the age of 39 had a statistically decreased survival compared to... (More)
Background. For Diffuse large B-cell lymphoma (DLBCL), the International Prognostic Index is the major tool for prognostication and considers an age above 60 years as a risk factor. However, there are several indications that increasing age is associated with more biological complexity, resulting in differences in DLBCL biology depending on age. Methods. We conducted a registry-based retrospective cohort study of all Swedish DLBCL patients diagnosed 2000-2013, to evaluate the importance of age at diagnosis for survival of DLBCL patients. Results. In total, 7166 patients were included for further analysis. Survival declined for every 10-year age group and every age group above the age of 39 had a statistically decreased survival compared to the reference group of 20-29 years. In an analysis of relative survival, and in a multifactorial model adjusted for stage, ECOG performance status, serum lactate dehydrogenase and involvement of extranodal sites, each age group above age 39 had a significantly higher risk ratio (p = 0.01) compared to the reference group. Conclusion. This is one of the largest population-based studies of DLBCL published to date. In this study, age persisted as a signifi cant adverse risk factor for patients as young as 40 years, even after adjustment for other risk factors. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
54
issue
6
pages
916 - 923
publisher
Taylor & Francis
external identifiers
  • wos:000354479800015
  • scopus:84929320787
ISSN
1651-226X
DOI
10.3109/0284186X.2014.978367
language
English
LU publication?
yes
id
e6e42337-6fe3-470b-acb7-933720f91c21 (old id 7422672)
date added to LUP
2015-07-03 07:04:07
date last changed
2017-01-01 05:42:01
@article{e6e42337-6fe3-470b-acb7-933720f91c21,
  abstract     = {Background. For Diffuse large B-cell lymphoma (DLBCL), the International Prognostic Index is the major tool for prognostication and considers an age above 60 years as a risk factor. However, there are several indications that increasing age is associated with more biological complexity, resulting in differences in DLBCL biology depending on age. Methods. We conducted a registry-based retrospective cohort study of all Swedish DLBCL patients diagnosed 2000-2013, to evaluate the importance of age at diagnosis for survival of DLBCL patients. Results. In total, 7166 patients were included for further analysis. Survival declined for every 10-year age group and every age group above the age of 39 had a statistically decreased survival compared to the reference group of 20-29 years. In an analysis of relative survival, and in a multifactorial model adjusted for stage, ECOG performance status, serum lactate dehydrogenase and involvement of extranodal sites, each age group above age 39 had a significantly higher risk ratio (p = 0.01) compared to the reference group. Conclusion. This is one of the largest population-based studies of DLBCL published to date. In this study, age persisted as a signifi cant adverse risk factor for patients as young as 40 years, even after adjustment for other risk factors.},
  author       = {Hedstrom, Gustaf and Hagberg, Oskar and Jerkeman, Mats and Enblad, Gunilla},
  issn         = {1651-226X},
  language     = {eng},
  number       = {6},
  pages        = {916--923},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {The impact of age on survival of diffuse large B-cell lymphoma - a population-based study},
  url          = {http://dx.doi.org/10.3109/0284186X.2014.978367},
  volume       = {54},
  year         = {2015},
}